Success Metrics

Clinical Success Rate
58.3%

Based on 7 completed trials

Completion Rate
58%(7/12)
Active Trials
0(0%)
Results Posted
71%(5 trials)
Terminated
5(42%)

Phase Distribution

Ph phase_3
9
75%
Ph phase_1
1
8%
Ph phase_2
2
17%

Phase Distribution

1

Early Stage

2

Mid Stage

9

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
9(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

58.3%

7 of 12 finished

Non-Completion Rate

41.7%

5 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(7)
Terminated(5)

Detailed Status

Completed7
Terminated5

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
58.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 22 (16.7%)
Phase 39 (75.0%)

Trials by Status

completed758%
terminated542%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_3

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

NCT01829464
terminatedphase_3

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

NCT01829477
terminatedphase_3

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

NCT01481116
completedphase_2

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097
completedphase_2

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

NCT01414920
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01829464Phase 3

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Terminated
NCT01829477Phase 3

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Terminated
NCT01481116Phase 3

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

Terminated
NCT01007097Phase 2

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Completed
NCT01414920Phase 2

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Completed
NCT01647542Phase 3

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

Terminated
NCT01609582Phase 3

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Terminated
NCT01433406Phase 3

Long-term Study of TAK-875

Completed
NCT01585792Phase 3

Double Blind Comparative Study of TAK-875

Completed
NCT01433419Phase 3

Open-label Study of TAK-875

Completed
NCT01433393Phase 3

Double-blind Comparative Study of TAK-875

Completed
NCT00949091Phase 1

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12